Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Foamix Pharma Ord (FOMX)

Foamix Pharma Ord (FOMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019

Foamix Became a Wholly Owned Subsidiary of Menlo Therapeutics Upon Closing of Merger on March 9, 2020

FOMX : 2.99 (-7.72%)
MNLO : 2.88 (-8.28%)
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company") announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix") following the satisfaction of all...

MNLO : 2.88 (-8.28%)
FOMX : 2.99 (-7.72%)
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company") announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix") following the satisfaction of all...

MNLO : 2.88 (-8.28%)
FOMX : 2.99 (-7.72%)
Foamix Pharmaceuticals to Present at the Cowen and Company's 40th Annual Health Care Conference

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs...

FOMX : 2.99 (-7.72%)
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs...

FOMX : 2.99 (-7.72%)
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs...

FOMX : 2.99 (-7.72%)
Foamix and Menlo Announce Shareholder Approval of Proposed Merger

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder...

FOMX : 2.99 (-7.72%)
MNLO : 2.88 (-8.28%)
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today the publication of the Company's Phase 3 studies FX2016-11 and FX2016-12 (Studies...

FOMX : 2.99 (-7.72%)
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today the publication of the Company's Phase 3 studies FX2016-11 and FX2016-12 (Studies...

FOMX : 2.99 (-7.72%)
Actinic (Solar) Keratosis Treatment Market Analysis with Lucrative Strategies and Irreplaceable Counsel by 2025

The Big Market Research has recently added a new survey report to their vivid and dynamic database. They have formulated this report by taking into consideration all the key aspects that tend to have an...

ATNX : 7.53 (-12.95%)
FOMX : 2.99 (-7.72%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Actinic (Solar) Keratosis Treatment Market Development Study: Big changes will have a big Impact

HTF MI recently introduced latest version Actinic (Solar) Keratosis Treatment Market Study 2019. It covered product Scope, Market Share, Size, Revenue, Opportunities, Growth Rate, Sales Growth, Demand,...

FOMX : 2.99 (-7.72%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC ("OrbiMed"), a significant shareholder of the Company,...

FOMX : 2.99 (-7.72%)
OrbiMed Supports the Proposed Foamix Pharmaceuticals Ltd. And Menlo Therapeutics Inc. Merger

OrbiMed Advisors LLC ("OrbiMed"), on behalf of its clients, has evaluated the Joint Proxy Statement/Prospectus for the proposed merger of Foamix Pharmaceuticals Ltd. ("Foamix") and Menlo Therapeutics Inc....

FOMX : 2.99 (-7.72%)
Actinic (Solar) Keratosis Treatment Market to witness major growth in coming years

Ameco Research Presents “” New Document to its Studies Database. The Report Contain 116 Pages With Detailed Analysis.

ATNX : 7.53 (-12.95%)
FOMX : 2.99 (-7.72%)
NVS : 79.28 (-0.58%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Foamix Announces AMZEEQ(TM) (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced a coverage update for its novel AMZEEQ(TM) (minocycline) topical foam, 4%. AMZEEQ...

FOMX : 2.99 (-7.72%)
Foamix Announces AMZEEQ(TM) (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that its novel AMZEEQ(TM) (minocycline) topical foam, 4% will be available on...

FOMX : 2.99 (-7.72%)
Rigrodsky & Long, P.A. Files Class Action Suit Against Foamix Pharmaceuticals Ltd.

Rigrodsky & Long, P.A.:

FOMX : 2.99 (-7.72%)
Lifshitz & Miller LLP Announces Investigation of Carolina Financial Corporation, Craft Brew Alliance, Inc., Foamix Pharmaceuticals Ltd., Grubhub Inc., Lipocine Inc., Pattern Energy Group, Inc., TD Ameritrade Holding Corporation, and William Lyon Homes

Carolina Financial Corporation (CARO)

CARO : 24.70 (-6.86%)
BREW : 14.85 (+0.27%)
FOMX : 2.99 (-7.72%)
GRUB : 39.16 (+2.62%)
LPCN : 0.4281 (+1.93%)
PEGI : 26.74 (unch)
AMTD : 34.51 (-1.51%)
UBSI : 22.03 (-7.55%)
WLH : 24.37 (+2.57%)
Foamix Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update...

FOMX : 2.99 (-7.72%)
FOAMIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Foamix Pharmaceuticals Ltd. - FOMX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Foamix Pharmaceuticals Ltd. (NasdaqGS: FOMX ) to...

FOMX : 2.99 (-7.72%)
MNLO : 2.88 (-8.28%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -3.71 , SEDG -8.08 , THC -1.42 , TER -2.66 , LITE -1.30
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar